These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27859651

  • 1. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, Brooks DJ, Ray-Chaudhuri K, Piccini P.
    Mov Disord; 2017 Feb; 32(2):235-240. PubMed ID: 27859651
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P, Fasano A, Cannas A, Mulas CS, Marrosu MG, Lang AE, Marrosu F.
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [Abstract] [Full Text] [Related]

  • 4. Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients.
    Politis M, Wilson H, Wu K, Brooks DJ, Piccini P.
    Neuroimage Clin; 2017 Aug; 16():455-460. PubMed ID: 28879087
    [Abstract] [Full Text] [Related]

  • 5. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
    Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study Group.
    Lancet Neurol; 2014 Feb; 13(2):141-9. PubMed ID: 24361112
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Costanzo AM, Gualberti G, Melzi G, di Luzio Paparatti U, Antonini A.
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [Abstract] [Full Text] [Related]

  • 8. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Senek M, Nielsen EI, Nyholm D.
    Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
    [Abstract] [Full Text] [Related]

  • 9. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L, Bove F, Espay KJ, Lena F, Modugno N, Poon YY, Krikorian R, Espay AJ, Fasano A.
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.
    Nyholm D, Adnan M, Senek M.
    J Parkinsons Dis; 2020 Apr; 10(4):1529-1534. PubMed ID: 32651335
    [Abstract] [Full Text] [Related]

  • 12. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D.
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [Abstract] [Full Text] [Related]

  • 13. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, Ferreira JJ, Palermo S, Lopiano L.
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [Abstract] [Full Text] [Related]

  • 14. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
    Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P.
    Neurology; 2006 Nov 14; 67(9):1612-7. PubMed ID: 17101892
    [Abstract] [Full Text] [Related]

  • 15. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
    Nyholm D, Klangemo K, Johansson A.
    Eur J Neurol; 2012 Aug 14; 19(8):1079-85. PubMed ID: 22360705
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.
    Neurology; 1996 May 14; 46(5):1430-6. PubMed ID: 8628494
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E, Segura B, Obeso I, Cho SS, Houle S, Lang AE, Rusjan P, Sandor P, Strafella AP.
    Hum Brain Mapp; 2015 Jul 14; 36(7):2592-601. PubMed ID: 25788222
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.